The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Open accessAbstract
A main limitation of therapies that selectively target kinase signalling pathways is the emergence of secondary drug resistance. Cetuximab, a monoclonal antibody that binds the extracellular domain of epidermal growth factor receptor (EGFR), is effective in a subset of KRAS wild-type metastatic colorectal cancers. After an initial response, secondary resistance invariably ensues, thereby limiting the clinical benefit of this drug. The molecular bases of secondary resistance to cetuximab in colorectal cancer are poorly understood. Here we show that molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers. Expression of mutant KRAS under the control of its endogenous gene promoter was sufficient to confer cetuximab resistance, but resistant cells remained sensitive to combinatorial inhibition of EGFR and mitogen-activated protein-kinase kinase (MEK). Analysis of metastases from patients who developed resistance to cetuximab or panitumumab showed the emergence of KRAS amplification in one sample and acquisition of secondary KRAS mutations in 60% (6 out of 10) of the cases. KRAS mutant alleles were detectable in the blood of cetuximab-treated patients as early as 10 months before radiographic documentation of disease progression. In summary, the results identify KRAS mutations as frequent drivers of acquired resistance to cetuximab in colorectal cancers, indicate that the emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression and suggest early initiation of a MEK inhibitor as a rational strategy for delaying or reversing drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients who initially respond to anti-EGFR develop acquired resistance within 12 to 18 months due to secondary mutations in KRAS genes, EGFR exodomain alteration, and clonal selection [9].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We and others previously reported that KRAS acquired mutations are responsible for secondary resistance to anti-EGFR therapies in CRC(22, 23).”
From EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. (2020) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“Patients who fail to respond to therapy initially exhibit intrinsic resistance, whereas those who relapse after initial response are associated with acquired resistance [9].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [9]
In the citing paper
“Emergence of KRAS amplification and acquisition of secondary KRAS mutations (G12C, G12D, G13D and Q61H) was detected as one mechanism of acquired resistance in metastatic CRC patients, who relapsed on cetuximab or panitumumab treatment (78, 79).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [78]
In the citing paper
“KRAS point mutations and gene copy number gains are responsible not only for primary but also for acquired resistance in 38–60 % of patients who relapse on cetuximab or panitumumab [37-39].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [38]
In the citing paper
“KRAS alterations could be identified noninvasively 5–10 months before radiographic disease progression by analyzing cell-free circulating tumor DNA (ctDNA) [37, 38].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [38]
In the citing paper
“however, the proof of principle that such an approach could complement tumor biopsy and provide an early warning of acquired resistance has been established [38, 41, 136].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [38]
In the citing paper
“To address these challenges, Mirati Therapeutics conducted high-resolution crystal structure analyses of compounds bound to mutant KRAS proteins, optimizing these compounds to develop MRTX1133, a non-covalent, selective inhibitor for KRAS G12D [60].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [60]
In the citing paper
“For instance, BRAF (V600E) and MAP2K1/MEK1 (K57T, K57N, I99_K104 deletion, and E102_I103 deletion) can also cause acquired drug resistance [94, 108–111].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [110]
In the citing paper
“By performing repeat biopsies and evaluating circulating tumor DNA, investigators observed the emergence of KRAS mutations as a resistance mechanism (Diaz et al., 2012; Misale et al., 2012).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Misale et al., 2012
In the citing paper
“non-invasive measures such as molecular interrogation of circulating tumor cells or plasma DNA may help capture the heterogeneity of resistance in patients, as was done to identify the development of KRAS mutations in colorectal cancers that acquire resistance to cetuximab (Diaz et al., 2012; Misale et al., 2012).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Misale et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationCirculating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationEGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,095
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Self-citationMolecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
Self-citationActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574
Flagged first, then by citations
2 of the 25 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 1,014
Acquired resistance in cancer: towards targeted therapeutic strategies
Soragni, A., Knudsen, E. S., O’Connor, T. N., Tognon, C. E., Tyner, J. W., Gini, B., Kim, D., Bivona, T. G., Zang, X., Witkiewicz, A. K., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00824-9 · Cited by 151
Troiani, T., Martinelli, E., Napolitano, S., Vitagliano, D., Ciuffreda, L. P., Costantino, S., Morgillo, F., Capasso, A., Sforza, V., Nappi, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0423 · Cited by 150
Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset
Agnoletto, C., Corrà, F., Minotti, L., Baldassari, F., Crudele, F., Cook, W. J. J., Leva, G. D., D’Adamo, P., Gasparini, P., & Volinia, S. (2019) · Cancers · doi:10.3390/cancers11040483 · Cited by 148
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.
Luraghi, P., Reato, G., Cipriano, E., Sassi, F., Orzan, F., Bigatto, V., De Bacco, F., Menietti, E., Han, M., Rideout, W. M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2340-t · Cited by 146
Morkel, M., Riemer, P., Bläker, H., & Sers, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4750 · Cited by 146
Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine
Rossi, G., & Ignatiadis, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3402 · Cited by 146
The dynamic range of circulating tumor DNA in metastatic breast cancer
Heidary, M., Auer, M., Ulz, P., Heitzer, E., Petru, E., Gasch, C., Riethdorf, S., Mauermann, O., Lafer, I., Pristauz, G., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0421-y · Cited by 145
Tumor heterogeneity in the clinic: is it a real problem?
Jankú, F. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834013517414 · Cited by 144
Mathematical modeling and computational prediction of cancer drug resistance
Sun, X., & Hu, B. X. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx065 · Cited by 142
Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations
Castro-Giner, F., Gkountela, S., Donato, C., Alborelli, I., Quagliata, L., Ng, C. K. Y., Piscuoglio, S., & Aceto, N. (2018) · Diagnostics · doi:10.3390/diagnostics8020031 · Cited by 142
Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution
Zhao, B., Sedlak, J. C., Srinivas, R. R., Creixell, P., Pritchard, J. R., Tidor, B., Lauffenburger, D. A., & Hemann, M. T. (2016) · Cell · doi:10.1016/j.cell.2016.01.045 · Cited by 139
Personalizing Oncology: Perspectives and Prospects
Mendelsohn, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3605 · Cited by 137
Cancer biomarker discovery: Current status and future perspectives
Mäbert, K., Cojoc, M., Peitzsch, C., Kurth, I., Souchelnytskyi, S., & Dubrovska, A. (2014) · International Journal of Radiation Biology · doi:10.3109/09553002.2014.892229 · Cited by 137
Cell-free circulating tumor DNA in cancer
Qin, Z., Ljubimov, V. A., Zhou, C., Tong, Y., & Liang, J. (2016) · 癌症：英文版 · doi:10.1186/s40880-016-0092-4 · Cited by 137
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
Acar, A., Nichol, D., Fernández-Mateos, J., Cresswell, G. D., Barozzi, I., Hong, S. P., Trahearn, N., Spiteri, I., Stubbs, M., Burke, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15596-z · Cited by 137
Crisafulli, G., Bianchi, A. S., Lazzari, L., Pietrantonio, F., Amatu, A., Macagno, M., Barault, L., Cassingena, A., Bartolini, A., Luraghi, P., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1434 · Cited by 137
Self-citationMontagut, C., Argilés, G., Ciardiello, F., Poulsen, T. T., Dienstmann, R., Kragh, M., Kopetz, S., Lindsted, T., Ding, C., Vidal, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5245 · Cited by 135
Self-citationHe, J., Qiu, Z., Fan, J., Xie, X., Sheng, Q., & Sui, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01891-4 · Cited by 134
Multi-omics strategies for biomarker discovery and application in personalized oncology
Jiang, Z., Zhang, H., Gao, Y., & Sun, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00340-0 · Cited by 143
Alborelli, I., Generali, D., Jermann, P. M., Cappelletti, M. R., Ferrero, G., Scaggiante, B., Bortul, M., Zanconati, F., Nicolet, S., Haegele, J., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1770-3 · Cited by 133
Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy
Hong, S. P., Chan, T. E., Lombardo, Y., Corleone, G., Rotmensz, N., Bravaccini, S., Rocca, A., Pruneri, G., McEwen, K. R., Coombes, R. C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11721-9 · Cited by 133
Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives
Geng, F., Wang, Z., Yin, H. H., Yu, J., & Cao, B. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2210 · Cited by 132
Zhang, J., Lin, B., Wu, L., Huang, M., Li, X., Zhang, H., Song, J. T., Wang, W., Zhao, G., Song, Y., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202005974 · Cited by 132
LncRNA DLEU1 contributes to colorectal cancer progression via activation of KPNA3
Liu, T., Han, Z., Li, H. Z., Zhu, Y., Sun, Z., & Zhu, A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0873-2 · Cited by 131
Circulating tumor cells and DNA as liquid biopsies
Heitzer, E., Auer, M., Ulz, P., Geigl, J. B., & Speicher, M. R. (2013) · Genome Medicine · doi:10.1186/gm477 · Cited by 130
Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion
Jiang, H., Liu, X., Knolhoff, B. L., Hegde, S., Lee, K. B., Jiang, H., Fields, R. C., Pachter, J. A., Lim, K.-H., & DeNardo, D. G. (2020) · Gut · doi:10.1136/gutjnl-2018-317424 · Cited by 130
Gay, L. J., Baker, A., & Graham, T. A. (2016) · F1000Research · doi:10.12688/f1000research.7210.1 · Cited by 129
Wong, C. C., Qian, Y., Li, X., Xu, J., Kang, W., TONG, J. H. M., To, K., Ye, J., Li, W., Chen, H., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.07.011 · Cited by 129
The value of cell‐free DNA for molecular pathology
Stewart, C. M., Kothari, P. D., Mouliere, F. C., Mair, R. J., Somnay, S., Benayed, R., Zehir, A., Weigelt, B., Dawson, S., Arcila, M. E., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5048 · Cited by 129
Suzawa, K., Offin, M. D., Lu, D., Kurzatkowski, C., Vojnic, M., Smith, R. S., Sabari, J. K., Tai, H., Mattar, M. S., Khodos, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1640 · Cited by 129
Underlying Mechanisms for Distant Metastasis - Molecular Biology
Pachmayr, E., Treese, C., & Stein, U. (2017) · Visceral Medicine · doi:10.1159/000454696 · Cited by 128
Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation
Boyle, K. A., Wickle, J. V., Hill, R. B., Marchese, A., Kalyanaraman, B., & Dwinell, M. B. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001469 · Cited by 130
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 133
Suto, T., Yokobori, T., Yajima, R., Morita, H., Fujii, T., Yamaguchi, S., Altan, B., Tsutsumi, S., Asao, T., & Kuwano, H. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu242 · Cited by 127
Maron, S. B., Alpert, L., Kwak, H. A., Lomnicki, S., Chase, L. M., Xu, D., O’Day, E., Nagy, R. J., Lanman, R. B., Cecchi, F., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1260 · Cited by 128
Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action
Heinemann, V., Douillard, J., Ducreux, M. P., & Peeters, M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.011 · Cited by 126
Biopsies: next-generation biospecimens for tailoring therapy
Basik, M., Aguilar‐Mahecha, A., Rousseau, C., Diaz, Z., Tejpar, S., Spatz, A., Greenwood, C. M. T., & Batist, G. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.101 · Cited by 126
Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer
Hench, I. B., Hench, J., & Tolnay, M. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00009 · Cited by 126
Fernández-García, D., Hills, A., Page, K., Hastings, R. K., Toghill, B. J., Goddard, K. S., Ion, C., Ogle, O., Boydell, A., Gleason, K. L. T., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1235-8 · Cited by 126
Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer
Spindler, K.-L. G., Pallisgaard, N., Andersen, R. F., Brandslund, I., & Jakobsen, A. K. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0108247 · Cited by 124
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
Knickelbein, K., & Zhang, L. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.10.002 · Cited by 124
Parseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 124
Sforza, V., Martinelli, E., Ciardiello, F., Gambardella, V., Napolitano, S., Martini, G., della Corte, C., Cardone, C., Ferrara, M. L., Reginelli, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6345 · Cited by 123
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
Misale, S., Bozic, I., Tong, J., Peraza-Penton, A., Lallo, A., Baldi, F., Lin, K. H., Truini, M., Trusolino, L., Bertotti, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9305 · Cited by 122
Self-citationTosi, F., Magni, E., Amatu, A., Mauri, G., Bencardino, K. B., Truini, M., Veronese, S. M., Carlis, L. G. D., Ferrari, G. C., Nichelatti, M., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.004 · Cited by 122
Self-citationAntibody-Mediated Delivery of Anti– KRAS -siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer
Bäumer, S., Bäumer, N., Appel, N., Terheyden, L., Fremerey, J., Schelhaas, S., Wardelmann, E., Buchholz, F., Berdel, W. E., & Müller‐Tidow, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2017 · Cited by 122
Espósito, A., Bardelli, A., Criscitiello, C., Colombo, N., Gelao, L., Fumagalli, L. A. M., Minchella, I., Locatelli, M., Goldhirsch, A., & Curigliano, G. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.003 · Cited by 121
Self-citationGenomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges
Dienstmann, R., Rodon, J. A., Barretina, J., & Tabernero, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2268 · Cited by 120
Hedgehog pathway inhibition and the race against tumor evolution
Atwood, S. X., Chang, A. L. S., & Oro, A. E. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201207140 · Cited by 118
Signaling cross-talk in the resistance to HER family receptor targeted therapy
Yamaguchi, H., Chang, S. H., Hsu, J. L., & Hung, M. (2013) · Oncogene · doi:10.1038/onc.2013.74 · Cited by 118
Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA
Chaudhuri, A. A., Binkley, M. S., Osmundson, E. C., Alizadeh, A. A., & Diehn, M. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.05.001 · Cited by 117
Hobor, S., Emburgh, B. O. V., Crowley, E. H., Misale, S., Nicolantonio, F. D., & Bardelli, A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0774 · Cited by 117
Self-citationThe Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials
Hervieu, C., Christou, N., Battu, S., & Mathonnet, M. (2021) · Cancers · doi:10.3390/cancers13051092 · Cited by 116
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better
Andrei, P., Battuello, P., Grasso, G., Rovera, E., Tesio, N., & Bardelli, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.007 · Cited by 116
Self-citationOsumi, H., Shinozaki, E., Yamaguchi, K., & Zembutsu, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-53711-3 · Cited by 114
Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers
Božić, I., & Nowak, M. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412075111 · Cited by 114
DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer
Mamlouk, S., Childs, L. H., Aust, D. E., Heim, D., Melching, F., de Oliveira, C. M. M., Wolf, T. A., Durek, P., Schumacher, D., Bläker, H., et al. (2017) · Nature Communications · doi:10.1038/ncomms14093 · Cited by 114
Perkins, G., Lu, H., Garlan, F., & Taly, V. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.10.001 · Cited by 114
Oikonomou, E., Koustas, E., Goulielmaki, M., & Pintzas, A. (2014) · Oncotarget · doi:10.18632/oncotarget.2555 · Cited by 113
Do, H., Wong, S. Q., Li, J., & Dobrovic, A. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.202390 · Cited by 113
Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis
Chen, D., Liang, W., Yu, J., & Zhang, L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2944 · Cited by 113
Picco, G., Cattaneo, C. M., van Vliet, E. J., Crisafulli, G., Rospo, G., Consonni, S., Vieira, S. F., Sánchez-Rodríguez, I., Cancelliere, C., Banerjee, R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1508 · Cited by 112
Self-citationButler, T. M., Johnson-Camacho, K., Peto, M., Wang, N. J., Macey, T. A., Korkola, J. E., Koppie, T. M., Corless, C. L., Gray, J. W., & Spellman, P. T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136407 · Cited by 111
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Perez‐Gracia, J. L., Sanmamed, M. F., Bosch, A., Patiño‐García, A., Schalper, K. A., Segura, V., Joaquim Bellmunt, B., Tabernero, J. M., Sweeney, C. J., Choueiri, T. K., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.005 · Cited by 112
Espósito, A., Criscitiello, C., Locatelli, M., Milano, M., & Curigliano, G. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.007 · Cited by 110
Schwaederle, M. C., Chattopadhyay, R., Kato, S., Fanta, P. T., Banks, K. C., Choi, I. S., Piccioni, D. E., Ikeda, S., Talasaz, A. H., Lanman, R. B., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0885 · Cited by 110
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets
Palmieri, G., Ombra, M. N., Colombino, M., Casula, M., Sini, M. C., Manca, A., Paliogiannis, P., Ascierto, P. A., & Cossu, A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00183 · Cited by 110
Do mutator mutations fuel tumorigenesis?
Fox, E. J., Prindle, M. J., & Loeb, L. A. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9426-8 · Cited by 109
Circulating cell-free DNA for non-invasive cancer management
Stewart, C. M., & Tsui, D. W. Y. (2018) · Cancer Genetics · doi:10.1016/j.cancergen.2018.02.005 · Cited by 109
Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review
Vymetalkova, V. P., Červená, K., Bartu, L., & Vodička, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113356 · Cited by 109
Bruun, J., Kryeziu, K., Eide, P. W., Moosavi, S. H., Eilertsen, I. A., Langerud, J., Røsok, B. I., Totland, M. Z., Brunsell, T. H., Pellinen, T. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3637 · Cited by 111
Li, Z., Zhao, L., Yu, L., & Wei, M. (2020) · Gastroenterology report · doi:10.1093/gastro/goaa022 · Cited by 110
Wei, X., Yang, J., Adair, S. J., Öztürk, H., Kuscu, C., Lee, K. Y., Kane, W. J., O’Hara, P. E., Liu, D., Demirlenk, Y. M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009899117 · Cited by 109
The feasibility of using mutation detection in ctDNA to assess tumor dynamics
Yi, X., Ma, J., Guan, Y., Chen, R., Yang, L. M., & Xia, X. (2017) · International Journal of Cancer · doi:10.1002/ijc.30620 · Cited by 108
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours
Crucitta, S., Cucchiara, F., Mathijssen, R. H. J., Mateo, J., Jager, A., Joosse, A., Passaro, A., Attili, I., Petrini, I., van Schaik, R. H., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102340 · Cited by 106
Ng, S., Tan, W. J., Pek, M. M. X., Tan, M.-H., & Kurisawa, M. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119400 · Cited by 105
Intratumor heterogeneity alters most effective drugs in designed combinations
Zhao, B., Hemann, M. T., & Lauffenburger, D. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323934111 · Cited by 105
Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring
Kang, Z., Stevanović, S., Hinrichs, C. S., & Cao, L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1553 · Cited by 105
Troiani, T., Napolitano, S., Vitagliano, D., Morgillo, F., Capasso, A., Sforza, V., Nappi, A., Ciardiello, D., Ciardiello, F., & Martinelli, E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2181 · Cited by 104
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000088 · Cited by 104
Cancer genome-sequencing study design
Mwenifumbo, J. C., & Marra, M. A. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3445 · Cited by 104
Kidess, E., & Jeffrey, S. S. (2013) · Genome Medicine · doi:10.1186/gm474 · Cited by 104
Understanding Inter-Individual Variability in Monoclonal Antibody Disposition
Thomas, V. A., & Balthasar, J. P. (2019) · Antibodies · doi:10.3390/antib8040056 · Cited by 106
Combinatorial strategies to target RAS-driven cancers
Perurena, N., Situ, L., & Cichowski, K. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00679-6 · Cited by 107
Dong, L., Wang, S., Fu, B., & Wang, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-27368-3 · Cited by 102
Bangi, E., Ang, C., Smibert, P., Uzilov, A. V., Teague, A., Antipin, Y., Chen, R., Hecht, C., Gruszczynski, N., Yon, W. J., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav6528 · Cited by 102
Chitalia, R., Rowland, J., McDonald, E. S., Pantalone, L., Cohen, E. A., Gastounioti, A., Feldman, M. D., Schnall, M. D., Conant, E. F., & Despina Kontos, B. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4067 · Cited by 102
García‐Foncillas, J., Alba, E., Aranda, E., Díaz‐Rubio, E., López‐López, R., Tabernero, J. M., & Vivancos, A. P. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx501 · Cited by 102
Challenges and achievements of liquid biopsy technologies employed in early breast cancer
Alba-Bernal, A., Lavado-Valenzuela, R., Domínguez-Recio, M. E., Jiménez-Rodríguez, B., Queipo‐Ortuño, M. I., Alba, E., & Comino‐Méndez, I. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103100 · Cited by 101
Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia
Toledo, R. A., Jiménez, C., Armaiz-Peña, G., Arenillas, C., Capdevila, J., & Dahia, P. L. M. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac025 · Cited by 103
Vignot, S., Lefèbvre, C., Frampton, G. M., Meurice, G., Yelensky, R., Palmer, G. A., Capron, F., Lazar, V., Hannoun, L., Miller, V. A., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.02.012 · Cited by 100
Kidess, E., Heirich, K., Wiggin, M., Vysotskaia, V. S., Visser, B. C., Marziali, A., Wiedenmann, B., Norton, J. A., Lee, M., Jeffrey, S. S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3041 · Cited by 99
Role of targeted therapy in metastatic colorectal cancer
Ohhara, Y., Fukuda, N., Takeuchi, S., Honma, R., Shimizu, Y., Kinoshita, I., & Dosaka‐Akita, H. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i9.642 · Cited by 99
Siena, S., Bianchi, A. S., García‐Carbonero, R., Karthaus, M., Smith, D. M., Tabernero, J. M., Cutsem, E. V., Guan, X., Boedigheimer, M. J., Ang, A. L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx504 · Cited by 99
Self-citationIncorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
Yang, M., Forbes, M. E., Bitting, R. L., O’Neill, S. S., Chou, P. C., Topaloĝlu, Ü., Miller, L. D., Hawkins, G. A., Grant, S. C., DeYoung, B. R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx766 · Cited by 99
Thierry, A. R., Pastor, B., Jiang, Z.-Q., Κατσιαμπούρα, Α., Parseghian, C. M., Loree, J. M., Overman, M. J., Sánchez, C., Messaoudi, S. E., Ychou, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0232 · Cited by 98
Okajima, W., Komatsu, S., Ichikawa, D., Miyamae, M., Ohashi, T., Imamura, T., Kiuchi, J., Nishibeppu, K., Arita, T., Konishi, H., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i31.5650 · Cited by 98
Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
Ou, X., Gao, G., Habaz, I. A., & Wang, Y. (2024) · MedComm · doi:10.1002/mco2.694 · Cited by 104
Tonini, G., Imperatori, M., Vincenzi, B., Frezza, A. M., & Santini, D. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-92 · Cited by 98
Ma, F., Zhu, W., Guan, Y., Yang, L. M., Xia, X., Chen, S., Li, Q., Guan, X., Yi, Z., Qian, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11791 · Cited by 97
Metadata
- Authors
- Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., Bencardino, K., Cercek, A., Chen, C.-T., Veronese, S., Zanon, C., Sartore-Bianchi, A., Gambacorta, M., Gallicchio, M., Vakiani, E., Boscaro, V., Medico, E., Weiser, M., Siena, S., Di Nicolantonio, F., Solit, D., & Bardelli, A.
- Affiliations
- Candiolo Cancer Institute (IT)
- Memorial Sloan Kettering Cancer Center (US)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- University of Turin (IT)
- IFOM (IT)
- Corresponding author
- Solit, David
- Bardelli, Alberto
- ORCID
- Venue
- Nature
- Published
- 2012-06
- Volume
- 486
- Issue
- 7404
- Pages
- 532-536
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3927413
- OpenAlex
- W2062109911
- Cited by
- 1,889
- References
- 25
- Citations by year
- 2026: 75 · 2025: 73 · 2024: 81 · 2023: 115 · 2022: 129 · 2021: 138 · 2020: 134 · 2019: 163 · 2018: 161 · 2017: 171 · 2016: 177 · 2015: 163 · 2014: 145 · 2013: 133 · 2012: 28
- FWCI
- 73.66
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- European Commission (259015)
- Associazione Italiana per la Ricerca sul Cancro (5 x mille)
- Regione Piemonte
- National Cancer Institute (R01CA127240, P30CA008748, T32CA009207, R25CA020449)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS mutation, acquired drug resistance, anti-EGFR therapy, cetuximab resistance, colorectal cancer, EGFR, K-ras oncogene, circulating tumor DNA, tumor subclones, MEK inhibition, combination therapy, metastatic colorectal cancer, tumor heterogeneity
- MeSH terms
- Cetuximab, Panitumumab, Alleles, Antibodies, Monoclonal, Humans, Mutation, Promoter Regions, Genetic, Proto-Oncogene Proteins, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Disease Progression, ras Proteins, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
